Loading
CB
Calithera Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by DRACHMAN JONATHAN G, was filed 10 Nov 2021.
Insider Decl.
116
Thresholds
n/a
Buy Volume
€7M
15 ops. · all time
Sell Volume
€377,670
26 ops. · all time
Since the insiders bought
- -85.0%Entry US$17.42 · Close at T+365 US$2.61
- -85.0%Entry US$17.42 · Close at T+365 US$2.61
- -85.0%Entry US$17.42 · Close at T+365 US$2.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$41.8M
Net income-US$39.7M0.0% margin
Valuation
Beta-1.54
Balance sheet & cash
Total debtUS$1.7M
Free Cash Flow-US$43.7M
Debt / Equity8%
Profitability & ownership
ROE-114.1%
ROA-56.3%
% institutions0.0%
Last declaration on 31 January 2023
Declarations116 total
1,172 shares@ US$0.00030.0% of flowCommon StockSEC:0000899243-23-003071:1
120,161 shares@ US$0.3858100.0% of flowCommon StockSEC:0000899243-23-003071:0
526 shares@ US$0.4461100.0% of flowCommon StockSEC:0000899243-23-002610:0
217 shares@ US$0.4461100.0% of flowCommon StockSEC:0000899243-23-002608:0
317 shares@ US$0.4461100.0% of flowCommon StockSEC:0000899243-23-002609:0
79 shares@ US$0.446110.1% of flowCommon StockSEC:0000899243-23-002611:0
279 shares@ US$0.4461100.0% of flowCommon StockSEC:0000899243-23-002612:0
666 shares@ US$0.491589.9% of flowCommon StockSEC:0000899243-22-003134:0
5,586 shares@ €0.43449.3% of flowCommon StockSEC:0000899243-22-003138:0
4,794 shares@ €0.43448.2% of flowCommon StockSEC:0000899243-22-003139:0
4,794 shares@ €0.43448.2% of flowCommon StockSEC:0000899243-22-003135:0
18,077 shares@ €0.584341.8% of flowCommon StockSEC:0000899243-22-001301:0
18,077 shares@ €0.584340.7% of flowCommon StockSEC:0000899243-22-001298:0
18,077 shares@ €0.584341.8% of flowCommon StockSEC:0000899243-22-001299:0
3,855 shares@ €0.584344.3% of flowCommon StockSEC:0000899243-22-001300:0
48,190 shares@ US$0.88Common StockSEC:0000899243-21-044426:1
30,000 shares@ US$0.8565100.0% of flowCommon StockSEC:0000899243-21-044426:0
100,000 shares@ US$0.846799.7% of flowCommon StockSEC:0000899243-21-044154:0
Canonical exit: 8 Feb 2022 (T+90)
200,000 shares@ US$0.8595100.0% of flowCommon StockSEC:0000899243-21-044150:0
Canonical exit: 8 Feb 2022 (T+90)
100,000 shares@ US$0.846799.9% of flowCommon StockSEC:0000899243-21-044145:0
Canonical exit: 8 Feb 2022 (T+90)
15,566 shares@ US$0.00010.6% of flowCommon StockSEC:0000899243-21-043688:1
15,566 shares@ US$0.00010.5% of flowCommon StockSEC:0000899243-21-043687:1
3,077 shares@ US$0.00030.2% of flowCommon StockSEC:0000899243-21-043684:1
15,566 shares@ US$0.000113.7% of flowCommon StockSEC:0000899243-21-043680:1
51,810 shares@ US$0.84Common StockSEC:0000899243-21-043693:1
25 of 116 declarations
About Calithera Biosciences, Inc.
On November 10, 2021, 3 insiders at Calithera Biosciences, Inc. bought on the same day for EUR 294,285: EUR 148,247 for Jonathan G. Drachman, Director, and EUR 73,019 each for Susan Molineaux, President & CEO, and Christopher Molineaux, SR. VP, Development. The same day, Keith Orford, Director, sold for EUR 22,159. Orford has 18 filings including 14 sales. In all, 15 purchases, 10 of them with an amount, are worth EUR 294,313, but the median is only EUR 3, which shows that almost all the others are symbolic. The 26 sales, 7 of them with an amount, are worth EUR 64,757 (median EUR 13); the largest, EUR 42,552, is Deepika Pakianathan's, Director, on January 27, 2023. Adage Capital Partners GP, L.L.C. sold for EUR 13 on September 26, 2017. Purchases are 37% of open-market trades. The 116 filings from 14 filers were published from July 21, 2016 to January 31, 2023, peaking at 41 in 2021, with 48 grants and 21 option exercises, a median of 2 days after the trade. The US healthcare and pharma company has no filing in the last twelve months.
